ARTICLE | Product Development
Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients
October 13, 2020 12:22 AM UTC
Pivotal data in ulcerative colitis show two oral therapies — Jyseleca filgotinib from Gilead and Galapagos and Zeposia ozanimod from Bristol Myers Squibb — generating efficacy on par with biologics, with Jyseleca showing an edge in biologic-experienced patients.
Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) is the only oral therapy marketed for UC, but the JAK inhibitor has a black box warning regarding serious infections and malignancies, and competitors are close behind. ...